{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:49:58Z","timestamp":1782791398007,"version":"3.54.5"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2024-1143_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Mutations in the <jats:italic>GRN<\/jats:italic> gene encoded glycoprotein progranulin (PGRN), cause 5\u201310\u202f% of all cases of frontotemporal lobar degeneration (FTLD). The aim of our study was to verify the analytical and clinical performance of an automated chemiluminescent immunoassay method for PGRN measurement recently developed (Chorus Evo, Diesse Diagnostica, Italy).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-1143_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Five plasma pools and residual plasma samples (K<jats:sub>2<\/jats:sub>EDTA) from 25 control subjects (11 males, 62\u201379 years; 14 females, 54\u201376 years) and 151 patients (70 males, 53\u201381 years; 81 females, 44\u201382 years) with different neurodegenerative disorders (NDs), were assayed. In 61 out of 151 patients, genetic <jats:italic>GRN<\/jats:italic> screening was carried.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-1143_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Within-run imprecision (CV%) ranged from 3.8\u202f% (11.5\u202fpg\/L) to 10.8\u202f% (2.5\u202fpg\/L), and between-run, from 5.6\u202f% (68.7\u202fpg\/L) to 10.7\u202f% (2.8\u202fpg\/L). At genetic screening, 3 out of 61\u00a0patients were classified as <jats:italic>GRN<\/jats:italic>+ carriers, 18 as \u201cother mutations\u201d and 40 as \u201cno-mutations\u201d carriers. The PGRN median level in <jats:italic>GRN<\/jats:italic>+ carriers (15.9\u202fpg\/L) was significantly lower than that in control subjects (32.8\u202fpg\/L; p=0.006), in <jats:italic>GRN<\/jats:italic>\u2212 (27.50\u202fpg\/L; p=0.007), in other mutation carriers (24.80\u202fpg\/L; p=0.05) and in NDs patients (22.40\u202fpg\/L; p=0.05) ROC analysis, demonstrates the accuracy of progranulin levels in discriminating between \u201c<jats:italic>GRN<\/jats:italic>+\u201d and \u201c<jats:italic>GRN<\/jats:italic>\u2212\u201d carriers (AUC 0.985) as well as \u201c<jats:italic>GRN<\/jats:italic>+\u201d and \u201cother mutations\u201d carriers (AUC 0.870).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2024-1143_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The new automated progranulin method, for robust analytical performance, is suitable for use in the clinical setting, supporting clinicians in making a differential diagnosis in patients with neurodegenerative disorder.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2024-1143","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:21:01Z","timestamp":1737098461000},"page":"1118-1123","source":"Crossref","is-referenced-by-count":2,"title":["Progranulin measurement with a new automated method: a step forward in the diagnostic approach to neurodegenerative disorders"],"prefix":"10.1515","volume":"63","author":[{"given":"Chiara","family":"Cosma","sequence":"first","affiliation":[{"name":"Department of Medicine , University of Padova , Padova , Italy"},{"name":"QI.LAB.MED, Spin-off of the University , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Talli","sequence":"additional","affiliation":[{"name":"Department of Medicine , University of Padova , Padova , Italy"},{"name":"Laboratory Medicine Unit , University-Hospital , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pangrazzi","sequence":"additional","affiliation":[{"name":"Department of Medicine , University of Padova , Padova , Italy"},{"name":"QI.LAB.MED, Spin-off of the University , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-7885","authenticated-orcid":false,"given":"Andrea","family":"Padoan","sequence":"additional","affiliation":[{"name":"Department of Medicine , University of Padova , Padova , Italy"},{"name":"QI.LAB.MED, Spin-off of the University , Padova , Italy"},{"name":"Laboratory Medicine Unit , University-Hospital , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cerutti","sequence":"additional","affiliation":[{"name":"DIESSE Diagnostica Senese , Monteriggioni , Siena , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zaninotto","sequence":"additional","affiliation":[{"name":"QI.LAB.MED, Spin-off of the University , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gabelli","sequence":"additional","affiliation":[{"name":"Regional Brain Aging Centre , University-Hospital , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-1711","authenticated-orcid":false,"given":"Mario","family":"Plebani","sequence":"additional","affiliation":[{"name":"Department of Medicine , University of Padova , Padova , Italy"},{"name":"Laboratory Medicine Unit , University-Hospital , Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2025042506015783303_j_cclm-2024-1143_ref_001","doi-asserted-by":"crossref","unstructured":"van Swieten, JC, Heutink, P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7:965\u201374. https:\/\/doi.org\/10.1016\/s1474-4422(08)70194-7.","DOI":"10.1016\/S1474-4422(08)70194-7"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_002","doi-asserted-by":"crossref","unstructured":"Yu, C-E, Bird, TD, Bekris, LM, Montine, TJ, Leverenz, JB, Steinbart, E, et al.. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 2010:161\u201370. https:\/\/doi.org\/10.1001\/archneurol.2009.328.","DOI":"10.1001\/archneurol.2009.328"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_003","doi-asserted-by":"crossref","unstructured":"Meeter, LH, Patzke, H, Loewen, G, Dopper, EG, Pijnenburg, YA, van Minkelen, R, et al.. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. Dement Geriatr Cogn Dis Extra 2016;6:330\u201340. https:\/\/doi.org\/10.1159\/000447738.","DOI":"10.1159\/000447738"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_004","doi-asserted-by":"crossref","unstructured":"Hendriks, S, Peetom, K, Bakker, C, Koopmans, R, van der Flier, W, Papma, J, et al.. Global incidence of young-onset dementia: a systematic review and meta-analysis. Alzheimer\u2019s Dement 2023;19:831\u201343. https:\/\/doi.org\/10.1002\/alz.12695.","DOI":"10.1002\/alz.12695"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_005","doi-asserted-by":"crossref","unstructured":"Borroni, B, Libri, I, Rota, M, Binetti, G, Benussi, L, Ghidoni, R, et al.. Incidence of young-onset dementia in Italy: the Brescia register study. Alzheimer\u2019s Dement 2024;16:e12544. https:\/\/doi.org\/10.1002\/dad2.12544.","DOI":"10.1002\/dad2.12544"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_006","doi-asserted-by":"crossref","unstructured":"Ghidoni, R, Stoppani, E, Rossi, G, Piccoli, E, Albertini, V, Paterlini, A, et al.. Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. Neurodegener Dis 2012;9:121\u20137. https:\/\/doi.org\/10.1159\/000333132.","DOI":"10.1159\/000333132"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_007","doi-asserted-by":"crossref","unstructured":"Morenas-Rodriguez, E, Cervera-Carles, L, Vilaplana, E, Alcolea, D, Carmona-Iragui, M, Dols-Icardo, O, et al.. Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias. J Alzheimers Dis 2016;50:539\u201346. https:\/\/doi.org\/10.3233\/jad-150746.","DOI":"10.3233\/JAD-150746"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_008","doi-asserted-by":"crossref","unstructured":"Finch, N, Baker, M, Crook, R, Swanson, K, Kuntz, K, Surtees, R, et al.. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009;132:583\u201391. https:\/\/doi.org\/10.1093\/brain\/awn352.","DOI":"10.1093\/brain\/awn352"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_009","doi-asserted-by":"crossref","unstructured":"Ghirelli, A, Spinelli, EG, Canu, E, Domi, T, Basaia, S, Castelnovo, V, et al.. Case report: coexistence of C9orf72 expansion and progranulin mutation in a case of genetic frontotemporal dementia\u00a0\u2013 clinical features and neuroimaging correlates. J Neurol 2023;270:5102\u20139. https:\/\/doi.org\/10.1007\/s00415-023-11839-3.","DOI":"10.1007\/s00415-023-11839-3"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_010","doi-asserted-by":"crossref","unstructured":"Sellami, L, Rucheton, B, Ben Younes, I, Camuzat, A, Saracino, D, Rinaldi, D, et al.. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. Neurobiol Aging 2020;91:167 e1\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.02.014.","DOI":"10.1016\/j.neurobiolaging.2020.02.014"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_011","doi-asserted-by":"crossref","unstructured":"Swift, IJ, Sogorb-Esteve, A, Heller, C, Synofzik, M, Otto, M, Graff, C, et al.. Fluid biomarkers in frontotemporal dementia: past, present and future. J Neurol Neurosurg Psychiatry 2021;92:204\u201315. https:\/\/doi.org\/10.1136\/jnnp-2020-323520.","DOI":"10.1136\/jnnp-2020-323520"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_012","doi-asserted-by":"crossref","unstructured":"Meda, F, Simr\u00e9n, J, Borroni, B, Cantoni, V, Archetti, S, Biasiotto, G, et al.. Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias. Clin Chem Lab Med 2023;61:2195\u2013204. https:\/\/doi.org\/10.1515\/cclm-2023-0562.","DOI":"10.1515\/cclm-2023-0562"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_013","doi-asserted-by":"crossref","unstructured":"Cooper, YA, Nachun, D, Dokuru, D, Yang, Z, Karydas, AM, Serrero, G, et al.. Progranulin levels in blood in Alzheimer\u2019s disease and mild cognitive impairment. Ann Clin Transl Neurol 2018;5:616\u201329. https:\/\/doi.org\/10.1002\/acn3.560.","DOI":"10.1002\/acn3.560"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_014","doi-asserted-by":"crossref","unstructured":"Bonato, G, Antonini, A, Pistonesi, F, Campagnolo, M, Guerra, A, Biundo, R, et al.. Genetic mutations in Parkinson\u2019s disease: screening of a selected population from North-Eastern Italy. Neurol Sci 2025;46:165\u201374. https:\/\/doi.org\/10.1007\/s10072-024-07690-7.","DOI":"10.1007\/s10072-024-07690-7"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_015","doi-asserted-by":"crossref","unstructured":"Greaves, CV, Rohrer, J. An update on genetic frontotemporal dementia. J Neurol 2019;266:2075\u201386. https:\/\/doi.org\/10.1007\/s00415-019-09363-4.","DOI":"10.1007\/s00415-019-09363-4"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_016","doi-asserted-by":"crossref","unstructured":"Nichols, E, Szoeke, CEI, Vollset, SE, Abbasi, N, Abd-Allah, F, Abdela, J, et al.. Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:88\u2013106. https:\/\/doi.org\/10.1016\/s1474-4422(18)30403-4.","DOI":"10.1016\/S1474-4422(18)30403-4"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_017","doi-asserted-by":"crossref","unstructured":"Rhinn, H, Tatton, N, McCaughey, S, Kurnellas, M, Rosenthal, A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol Sci 2022;43:641\u201352. https:\/\/doi.org\/10.1016\/j.tips.2021.11.015.","DOI":"10.1016\/j.tips.2021.11.015"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_018","doi-asserted-by":"crossref","unstructured":"Amin, S, Carling, G, Gan, L. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. Curr Opin Neurobiol 2022;72:131\u20139. https:\/\/doi.org\/10.1016\/j.conb.2021.10.001.","DOI":"10.1016\/j.conb.2021.10.001"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_019","doi-asserted-by":"crossref","unstructured":"Townley, RA, Boeve, BF, Benarroch, EE. Progranulin: functions and neurologic correlations. Neurology 2018;90:118\u201325. https:\/\/doi.org\/10.1212\/wnl.0000000000004840.","DOI":"10.1212\/WNL.0000000000004840"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_020","doi-asserted-by":"crossref","unstructured":"Swift, JI, Rademakers, R, Finch, N, Baker, M, Ghidoni, R, Benussi, L, et al.. A systematic review of progranulin concentrations in biofluids in over 7,000 people\u00a0\u2013 assessing the pathogenicity of GRN mutations and other influencing factors. Alzheimer\u2019s Res Ther 2024;16:66. https:\/\/doi.org\/10.1186\/s13195-024-01420-z.","DOI":"10.1186\/s13195-024-01420-z"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_021","doi-asserted-by":"crossref","unstructured":"Galimberti, D, Fenoglio, C, Scarpini, E. Progranulin as a therapeutic target for dementia. Expert Opin Ther Targets 2018;22:579\u201385. https:\/\/doi.org\/10.1080\/14728222.2018.1487951.","DOI":"10.1080\/14728222.2018.1487951"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_022","doi-asserted-by":"crossref","unstructured":"Chouliaras, L, Thomas, A, Malpetti, M, Donaghy, P, Kane, J, Mak, E, et al.. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer\u2019s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2022;93:651\u20138. https:\/\/doi.org\/10.1136\/jnnp-2021-327788.","DOI":"10.1136\/jnnp-2021-327788"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_023","doi-asserted-by":"crossref","unstructured":"Currens, L, Harrison, N, Schmidt, M, Amjad, H, Mu, W, Scholz, SW, et al.. A case of familial frontotemporal dementia caused by a progranulin gene mutation. Clin Park Relat Disord 2023;9:100213. https:\/\/doi.org\/10.1016\/j.prdoa.2023.100213.","DOI":"10.1016\/j.prdoa.2023.100213"},{"key":"2025042506015783303_j_cclm-2024-1143_ref_024","doi-asserted-by":"crossref","unstructured":"Ntymenou, S, Tsantzali, I, Kalamatianos, T, Voumvourakis, KI, Kapaki, E, Georgios, T, et al.. Blood biomarkers in frontotemporal dementia: review and meta-analysis. Brain Sci 2021;11:244. https:\/\/doi.org\/10.3390\/brainsci11020244.","DOI":"10.3390\/brainsci11020244"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1143\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:04:19Z","timestamp":1745561059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2024-1143\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,5,26]]}},"alternative-id":["10.1515\/cclm-2024-1143"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2024-1143","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}